SARS-CoV |
|
|
|
|
|
|
Lee (2003) 39
|
138 |
Acute HF (1pt) |
None |
3.6% |
|
Booth (2003) 40
|
144
|
Pulse>100bpm (46%)
Chest pain (10.4%)
|
ND
|
6.5%
|
|
Li (2003) 23
|
46
|
RBBB 15.2%
LVEF-HF 1pt (EF 30.2%)
Initial TTE compare with 30 days control:
Lower LVEF
Lower Doppler-derived CO
|
ND
|
13%
|
|
Yu (2003) 7
|
121
|
Tachycardia (71.9%)
Hypotension (50.4%)
Bradycardia (14.9%)
Rev cardiomegaly (10.7%)
|
ND
|
ND
|
MERS-CoV |
Saad (2014) 13
|
70 |
Arrythmias
(15.7%) |
ND |
60% |
|
Al-Tawfiq (2014) 41
|
17
|
X-ray cardiomegaly (53%)
Chest pain (7%)
|
ND
|
76%
|
|
Assiri (2016) 43
|
47 |
Chest pain (15%) |
ND |
60% |
|
Al-Albdallat (2014) 14
|
9
|
Chest pain (44%)
Pericarditis (1 pt)
VT (1 pt)
SVT (1 pt)
|
ND
|
22%
|
H1N1 Influenza |
Schoen (2019) 42
|
160 |
Chest pain (5%) |
ND |
Zero |
SARS-CoV-2
|
Huang (2020) 20
|
41
|
Shock (7%)
|
Elevated in
12.2%
|
15%
|
|
Wang (2020) 2
|
118
|
Arrhythmia (16.7%)
Shock (8.7%)
Acute cardiac injury (7.2%)
|
Mean 6.4 pg/ml
|
4.3%
|
|
Shi (2020) 1
|
416
|
Chest pain (3.4%)
ST-depression ECG (0.7%)
|
Elevated in 19.7%
|
13.7%
|
|
Zhou (2020) 22
|
191
|
Heart Failure (23%)
Hypotension (1%)
HR>125bpm (1%)
|
Elevated in
17%
|
28.2%
|
|
Guo (2020) 21
|
187 |
VT/VF (5.9%) |
Elevated in
27.8% |
23% |